Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is an experimental small molecule with the chemical formula C20H20Cl2N2O5 and a molecular weight of approximately 439.29 g/mol[1][2]. It has been studied as a potential inhibitor of glycogen phosphorylase (muscle form), an enzyme involved in glycogen catabolism and glucose homeostasis[4]. The drug is not approved for any indication and has not advanced beyond preclinical or early experimental stages. No clinical trials or marketed products are associated with this compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-{3-[3-(2,4-dichloro-benzoyl)-ureido]-2-methyl-phenoxy}-pentanoic acid.